[{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","commit":"3b662d41c0","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for the last approved products without one","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab%20emtansine\" }]"}]},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"tldr","before":"\"The first ADC for a solid tumour (2013). Still standard after surgery for HER2+ breast cancer patients whose tumour did not fully respond to pre-surgery treatment.\"","after":"\"Trastuzumab emtansine (Kadcyla, T-DM1) was the first ADC for a solid tumour (2013). It is still standard after surgery for HER2+ breast cancer patients whose tumour did not fully respond to pre-surgery treatment.\""}]}]